

Cited in: *EMBASE/Excerpta Medica, Oncology Information Service, Elsevier BIOBASE/Current Awareness in Biological Sciences; Current Contents/Clinical Medicine; SciSearch, Index Medicus/MEDLINE. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.*

Reviews

- CT screening for lung cancer: Are we ready to implement in Europe?** 25
H. Balata, M. Evison, A. Sharman, P. Crosbie, R. Booton (UK)
- Endobronchial and surgical treatment of pulmonary carcinoid tumors: A systematic literature review** 85
E.M.B.P. Reuling, C. Dickhoff, P.W. Plaisier, H.J. Bonjer, J.M.A. Daniels (the Netherlands)
- Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis** 127
U. Dafni (Greece, Switzerland), Z. Tsourti, K. Vervita (Greece), S. Peters (Switzerland)
- First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light** 245
C.J. Ackermann (United Kingdom), M. Reck (Germany), L. Paz-Ares (Spain), F. Barlesi (France), R. Califano (United Kingdom)
- Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer** 259
B. Melosky, R. Juergens, D. McLeod, N. Leighl, A. Brade, P.B. Card, Q. Chu (Canada)

Original Research Articles

- Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer** 1
H. Hayashi, H. Iihara, C. Hirose, Y. Fukuda, M. Kitahora, D. Kaito, K. Yanase, J. Endo, Y. Ohno, A. Suzuki, T. Sugiyama
- Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma** 7
S. Park, J.H. Shim, B. Lee, I. Cho, W.-Y. Park, Y. Kim, S.-H. Lee, Y.L. Choi, J. Han, J.S. Ahn, M.-J. Ahn, K. Park, J.-M. Sun (Republic of Korea)
- Misclassification of the actual causes of death and its impact on analysis: A case study in non-small cell lung cancer** 16
K.S. Tan (United States)
- Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands** 34
M. van de Ven, V.P. Retèl, H. Koffijberg, W.H. van Harten (the Netherlands), M.J. IJzerman (the Netherlands, Australia)
- Impact of *KEAP1/NFE2L2/CUL3* mutations on duration of response to EGFR tyrosine kinase inhibitors in *EGFR* mutated non-small cell lung cancer** 42
J.A. Hellyer, H. Stehr, M. Das, S.K. Padda, K. Ramchandran, J.W. Neal, M. Diehn, H.A. Wakelee (USA)
- A phase Ib study of the combination of afatinib and ruxolitinib in *EGFR* mutant NSCLC with progression on *EGFR*-TKIs** 46
J.S. Park, M.H. Hong, Y.J. Chun, H.R. Kim, B.C. Cho (Republic of Korea)
- Guideline adherence of mediastinal staging of non-small cell lung cancer: A multicentre retrospective analysis** 52
J.E. Bousema, M. van Dorp, F. Hoeijmakers, I.A. Huijbregts, N.P. Barlo, G.P. Bootsma, W.P. van Boven, N.J.M. Claessens, A.-M.C. Dingemans, W.E. Hanselaar, R.Th.J. Kortekaas, J.-W.H.P. Lardenoije, J.G. Maessen, W.H. Schreurs, Y. Vissers, M. Youssef-El Soud, M.G.W. Dijkgraaf, JoukeT. Annema, F.J.C. van den Broek (the Netherlands)

(Contents continued overleaf)



Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC—A retrospective cohort study	
D. Lang, A. Horner, E. Brehm, K. Akbari, B. Hergan, K. Langer, C. Asel, M. Scala, B. Kaiser, B. Lamprecht (Austria)	59
Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme	
B. Ghimire, R. Maroni, D. Vulkan, Z. Shah, E. Gaynor, M. Timoney, L. Jones, R. Arvanitis, M. Ledson, L. Lukehurst, P. Rutherford, F. Clarke, K. Gardner, M.W. Marcus, S. Hill, D. Fideo, S. Mason, S.G. Smith, S.L. Quaife, K. Fitzgerald, V. Poirier, S.W. Duffy, J.K. Field (UK)	66
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance	
J. Zugazagoitia (Spain, USA), A. Gómez-Rueda, E. Jantus-Lewintre, D. Isla, C. Camps, I. Ramos, J.M. Trigo, R. Bernabé, O. Juan-Vidal, J.M. Sanchez-Torres, R. García-Campelo, M. Provencio, E. Felip, J. de Castro, I. Faull (Spain), R.B. Lanman (California), S. Ponce-Aix, L. Paz-Ares, P. Garrido (Spain)	72
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response	
A. Haragan, J.K. Field, M.P.A. Davies, C. Escriu (UK), A. Gruver (USA), J.R. Gosney (UK)	79
Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells	
H. Nakamura, M. Sugano, T. Miyashita, H. Hashimoto, A. Ochiai, K. Suzuki, M. Tsuboi, G. Ishii (Japan)	100
Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer	
B. Zhang, X. Niu, Q. Zhang, C. Wang, B. Liu, D. Yue, C. Li (China), G. Giaccone (China, USA), S. Li, L. Gao, H. Zhang, J. Wang, H. Yang, R. Wu, P. Ni, C. Wang, M. Ye, W. Liu (China)	108
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial	
A. Santo, S. Pilotto, D. Galetta (Italy), F. Grossi (Milano Italy), G. Fasola, G. Romano, L. Bonanno, A. Bearz, M. Papi, E. Roca, A. Catino, A. Follador, E. Rijavec, C. Genova, P. Petrillo, A. Favaretto, L. Giannone, M. Milella, G. Tortora, D. Giannarelli, E. Bria (Italy)	121
Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study	
A.J.W. Gibson, H. Li, A. D'Silva, A.A. Elegbede, R.A. Tudor, S. Otsuka, D.G. Bebb, W.Y. Cheung (Canada)	141
Evaluation of maximum standardized uptake value at fluorine-18 fluorodeoxyglucose positron emission tomography as a complementary T factor in the eighth edition of lung cancer stage classification	
H. Kim, J.M. Goo, J.C. Paeng, Y.T. Kim, C.M. Park (Republic of Korea)	151
Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer	
M.H. Hyun, E.S. Lee, J.S. Eo, S. Kim, E.J. Kang, J.S. Sung, Y.J. Choi, K.H. Park, S.W. Shin, S.Y. Lee, Y.H. Kim (Republic of Korea)	158
Homologous recombination and DNA repair mutations in patients treated with carboplatin and <i>nab</i>-paclitaxel for metastatic non-small cell lung cancer	
D.H. Owen, T.M. Williams, E.M. Bertino, X. Mo, A. Webb, C. Schweitzer, T. Liu, S. Roychowdhury, C.D. Timmers, G.A. Otterson (United States)	167
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study	
M. Dietel (Germany), N. Savelov (Russian Federation), R. Salanova (Argentina), P. Micke (Sweden), G. Bigras (Canada), T. Hida (Japan), J. Antunez (Spain), B. Guldhammer Skov (Denmark), G. Hutarew (Austria), L.F. Sua (Colombia), H. Akita (Japan), O.S.H. Chan (Hong Kong), B. Piperdi, T. Burke, S. Khambata-Ford, A.C. Deitz (USA)	174
Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer	
N. Kasahara, K. Kaira, K. Yamaguchi, H. Masubuchi, H. Tsurumaki, K. Hara, Y. Koga, R. Sakurai, T. Higuchi, T. Handa, T. Oyama, T. Yokobori, K. Shimizu, T. Asao, T. Hisada (Japan)	180
The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study	
P.N. Ding, T.M. Becker, V.J. Bray, W. Chua, Y.F. Ma, D. Lynch, J. Po, A.W.S. Luk, N. Caixeiro, P. de Souza, T.L. Roberts (Australia)	187

The expanding role of endobronchial ultrasound in patients with centrally located intrapulmonary tumors J.C. Kuijvenhoven (the Netherlands), V. Livi (Italy), L. Morandi (the Netherlands, Italy), A. Cancellieri (Italy), J.T. Annema (the Netherlands), R. Trisolini (Italy)	194
Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites K. Yoshimura, Y. Inoue, M. Karayama, K. Tsuchiya, K. Mori, Y. Suzuki, Y. Iwashita, T. Kahyo, A. Kawase, M. Tanahashi, H. Ogawa, K. Yokomura, N. Inui, K. Funai, K. Shinmura, H. Niwa, T. Suda, H. Sugimura (Japan)	202
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial E. Capelletto, M.R. Migliorino, A. Morabito, R. Chiari, F. Grossi, M. Tiseo, F.D. Costanzo, A. Delmonte, G. Romano, D. Galetta, V. Scotti, V. Gregorc, S. Pisconti, G.L. Ceresoli, A.D. Conte, L. Ciuffreda, I. Colantonio, E. Bria, S. Ricciardi, A. Manzo, G. Metro, A.M. Morelli, R. Critelli, M.V. Pacchiana, I. Stura, G. Migliaretti, S. Novello (Italy)	210
The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer Z. Liu, H. Liang, J. Lin, X. Cai, Z. Pan, J. Liu, X. Xie, C. Li, B. Cheng, Y. Zhao, J. He, W. Liang (China)	218
Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients I. Francaviglia, G. Magliacane, C. Lazzari, G. Grassini, E. Brunetto, E. Dal Cin, S. Girlando, D. Medicina, C.E. Smart, A. Bulotta, V. Gregorc, L. Pecciarini, C. Doglioni, M.G. Cangi (Italy)	225
Characterization of lung adenocarcinoma with a cribriform component reveals its association with spread through air spaces and poor outcomes Q. Ding, D. Chen, X. Wang, J. Wen, C. Chen, Y. Zhang, Z. Xu, Y. Chen (China)	238
UPSTAGING, CENTRALITY AND SURVIVAL IN EARLY STAGE NON-SMALL CELL LUNG CANCER VIDEO-ASSISTED SURGERY M. Boada, R. Guzmán, M. Montesinos, A. Libreros, A. Guirao, D. Sánchez-Lorente, JM. Gimferrer, A. Agustí, L. Molins (Spain)	254
Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial D. Fujimoto, M. Yomota, A. Sekine, M. Morita, T. Morimoto, Y. Hosomi, T. Ogura, H. Tomioka, K. Tomii (Japan)	274
<i>Short Communications</i>	
Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA J.G. Supplee, M.S.D. Milan, L.P. Lim, K.T. Potts, L.M. Sholl, G.R. Oxnard, C.P. Paweletz (USA)	96
Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer Y. Manjunath, S.V. Upparahalli, K.N. Suvilesh, D.M. Avella, E.T. Kimchi, K.F. Staveley-O'Carroll, G. Li, J.T. Kaifi (USA)	147
Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens A. Vannitamby, S. Hendry, L. Irving, D. Steinfors, S. Bozinovski (Australia)	233
<i>Case Reports</i>	
Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib N. Coleman, A. Wotherspoon, N. Yousaf, S. Popat (United Kingdom)	117
<i>Correspondence</i>	
Tuberous sclerosis complex: A rare etiology of multiple subsolid nodules L. Lantuéjoul (France), G. Pontarollo (France), E. Reymond (France), M. Brevet (France), F. Thivolet-Béjui (France), G.R. Ferretti (France)	268
Small cell lung cancer elevates procalcitonin levels in the absence of infection A.J. Pardo-Cabello (Spain), V. Manzano-Gamero (Spain)	272
<i>Corrigenda</i>	
Corrigendum to "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos" [Lung Cancer, 131 (May) (2019) 23-30] P. Maisonneuve, C. Rampinelli, R. Bertolotti, A. Misotti, F. Lococo, M. Casiraghi, L. Spaggiari, M. Bellomi, P. Novellis, M. Solinas, E. Dieci, M. Alloisio, L. Fontana, B. Persechino, S. Iavicoli, G. Veronesi (Italy)	279